Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in Sclerotic Chronic GVHD
NCT03616184Phase 2Completed
- Sponsor
- University of Nebraska
- Start
- Sep 2018
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in chronic graft-versus-host disease (cGVHD), sponsored by University of Nebraska. Primary endpoint: Percentage of Participants With Complete and Partial Responses in Skin and/or Joint at 6 months. Started Sep 2018; status: completed.
02
Drugs
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT03616184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03616184.